Outlook Therapeutics Inc (NASDAQ:OTLK)
| 0.4401 Delayed Data As of Dec 07 |  -0.0049 / -1.10%Today’s Change | 0.20 Today|||52-Week Range 2.03 | -59.25% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $123.0M |
Company Description
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Contact Information
Outlook Therapeutics, Inc. 485 Route 1 South Iselin New Jersey 08830 |
Employees
Shareholders
| Individual stakeholders | 65.37% |
| Mutual fund holders | 6.28% |
| Other institutional | 4.32% |
Top Executives
| C. Russell Trenary | President, Chief Executive Officer & Director |
| Lawrence A. Kenyon | CFO, Secretary, Treasurer & Director |
| Jennifer M. Kissner | SVP, Clinical & Regulatory Affairs |
| Surendra Sharma | Senior Vice President-Medical Affairs |
| Jeff Evanson | Chief Commercial Officer |
